Preparation and Stability Evaluation of Mesna Oral Solution From Commercially Available Tablets for Pediatric Patients

This research focused on the formulation and evaluation of a pediatric oral solution of mesna, a chemoprotective agent used to mitigate urotoxicity associated with chemotherapy drugs such as ifosfamide and cyclophosphamide. Given the challenges faced by pediatric patients in swallowing tablets, an extemporaneous oral solution was developed to improve accessibility and compliance. The formulation process involved adjusting the pH to approximately 3 using citric acid, which not only enhanced mesna's water solubility but also acted as an antioxidant and flavor enhancer. The study assessed the physicochemical stability of the mesna solution over a 90-day period, evaluating parameters such as color stability, pH consistency, and drug content. Results demonstrated that the oral solution maintained its physicochemical properties, with minimal changes in pH and drug concentration, indicating good stability under refrigerated conditions. Additionally, microbiological evaluations confirmed the safety of the formulation. This study highlights the potential of an extemporaneous mesna oral solution as a viable alternative for pediatric patients, ensuring effective treatment while addressing challenges related to medication administration or shortage.